Kimak-Pielas Agnieszka, Robak Ewa, Zajdel Radosław, Żebrowska Agnieszka
Department of Dermatology and Venereology, Teaching Hospital No 2, Lodz, 90-549, Poland.
Department of Dermatology, Medical University of Lodz, Lodz, 90-647, Poland.
Clin Cosmet Investig Dermatol. 2025 Jun 27;18:1615-1624. doi: 10.2147/CCID.S517656. eCollection 2025.
Biologic therapies have revolutionized psoriasis treatment, offering targeted interventions that significantly improve outcomes for patients with moderate to severe forms of the disease. In Poland, biologic treatment for psoriasis is funded through the National Health Service's B.47 program, available since 2013.
This study aimed to perform a retrospective analysis of the effectiveness of biologic treatments during the first year of therapy in patients with plaque psoriasis, treated with biologic agents under the B.47 program at a single center in Poland.
Medical records of patients with plaque psoriasis who were enrolled in the National Health Service's B.47 drug program at the dermatology department between January 1, 2013, and August 2, 2024, were reviewed. This retrospective chart review utilized secondary data from these records. Ultimately, 159 patients totaling 300 drug-periods were enrolled to the study.
Six distinct patterns of treatment response emerged within the first year. Anti-IL-17AF therapy achieved complete remission (PASI-100) in the shortest time (53.8 days vs 101.7 days for a total population, <0.05). While treatment effectiveness did not differ between bio-naive and non-bio-naive patients overall, repeated exposures to anti-TNF and anti-IL-12/23 therapies were associated with a diminished clinical response.
The study highlights the critical importance of strategic selection of the treatment to optimize long-term outcomes.
生物疗法彻底改变了银屑病的治疗方式，提供了针对性的干预措施，显著改善了中重度银屑病患者的治疗效果。在波兰，自2013年起，银屑病的生物治疗通过国家卫生服务局的B.47项目提供资金支持。
本研究旨在对波兰一家中心接受B.47项目生物制剂治疗的斑块状银屑病患者治疗第一年的生物治疗效果进行回顾性分析。
回顾了2013年1月1日至2024年8月2日期间在皮肤科参加国家卫生服务局B.47药物项目的斑块状银屑病患者的病历。这项回顾性图表审查利用了这些记录中的二手数据。最终，共有159名患者的300个药物治疗周期纳入研究。
在第一年出现了六种不同的治疗反应模式。抗IL-17AF疗法在最短时间内实现了完全缓解（PASI-100）（53.8天，而总体人群为101.7天，P<0.05）。虽然总体上生物制剂初治患者和非初治患者的治疗效果没有差异，但重复使用抗TNF和抗IL-12/23疗法与临床反应减弱有关。
该研究强调了战略选择治疗方法以优化长期治疗效果的至关重要性。
